FACTOR V Mutation Screening F5 – G1691A Test
Are you concerned about your risk of developing blood clots? DNA Labs UAE offers the FACTOR V Mutation Screening F5 – G1691A Test to help you understand your genetic predisposition. This comprehensive genetics test can provide valuable insights into your clotting risk and guide appropriate management strategies.
Test Details
The FACTOR V Mutation Screening F5 – G1691A Test refers to the process of testing for a specific genetic mutation in the Factor V gene, known as F5 – G1691A or Factor V Leiden mutation. Factor V is a protein involved in the blood clotting process. The F5 – G1691A mutation results in an altered form of Factor V that is resistant to inactivation by a natural anticoagulant called activated protein C. This resistance to inactivation can lead to an increased risk of abnormal blood clot formation, known as thrombophilia.
The screening for the F5 – G1691A mutation involves a simple blood test. A small sample of peripheral blood is collected from a vein in the arm and sent to our laboratory for analysis. Our experienced team uses state-of-the-art techniques, such as Real Time PCR and DNA sequencing, to detect the presence of the mutation.
Who Should Consider This Test?
The FACTOR V Mutation Screening F5 – G1691A Test is typically recommended for individuals who have a personal or family history of blood clots, especially if the clots occurred at a young age or in unusual locations. It may also be recommended for individuals who have recurrent pregnancy loss or a family history of thrombophilia.
Identifying the presence of the F5 – G1691A mutation can help in determining your risk for developing blood clots and guide appropriate management strategies. This may include lifestyle modifications, such as regular exercise and avoiding certain medications, as well as the use of anticoagulant medications to prevent blood clots.
It is important to note that the presence of the F5 – G1691A mutation does not necessarily mean that you will develop blood clots. Other genetic and environmental factors also contribute to the overall risk. Therefore, the screening results should be interpreted in the context of your overall health and medical history.
Test Cost and Report Delivery
The FACTOR V Mutation Screening F5 – G1691A Test is available at DNA Labs UAE for a cost of AED 1200.0. The test includes the collection of a 2ml peripheral blood sample in an EDTA Vacutainer. The report will be delivered within 3-4 days after the sample is received.
Consultation with a General Physician
A Doctor’s prescription is required for the FACTOR V Mutation Screening F5 – G1691A Test. Our test department is led by General Physicians who can provide the necessary consultation and guidance.
Pre Test Information
Please note that the FACTOR V Mutation Screening F5 – G1691A Test requires a Doctor’s prescription. However, the prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Take control of your health and gain valuable insights into your clotting risk with the FACTOR V Mutation Screening F5 – G1691A Test at DNA Labs UAE. Contact us today to schedule your appointment.
| Test Name | FACTOR V Mutation Screening F5 – G1691A Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 1200.0 AED |
| Sample Condition | Peripheral blood |
| Report Delivery | 3-4 days |
| Method | Real Time PCR |
| Test type | Genetics |
| Doctor | General Physician |
| Test Department: | |
| Pre Test Information | FACTOR V Mutation Screening (F5 – G1691A) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
Factor V mutation screening refers to the process of testing for a specific genetic mutation in the Factor V gene, known as F5 – G1691A. This mutation is also known as Factor V Leiden mutation. Factor V is a protein involved in the blood clotting process. The F5 – G1691A mutation results in an altered form of Factor V that is resistant to inactivation by a natural anticoagulant called activated protein C. This resistance to inactivation can lead to an increased risk of abnormal blood clot formation, known as thrombophilia. The screening for the F5 – G1691A mutation involves a simple blood test. The blood sample is usually collected from a vein in the arm and sent to a laboratory for analysis. The laboratory uses various techniques, such as polymerase chain reaction (PCR) and DNA sequencing, to detect the presence of the mutation. The screening is typically recommended for individuals who have a personal or family history of blood clots, especially if the clots occurred at a young age or in unusual locations. It may also be recommended for individuals who have recurrent pregnancy loss or a family history of thrombophilia. Identifying the presence of the F5 – G1691A mutation can help in determining the individual’s risk for developing blood clots and guide appropriate management strategies. This may include lifestyle modifications, such as regular exercise and avoiding certain medications, as well as the use of anticoagulant medications to prevent blood clots. It is important to note that the presence of the F5 – G1691A mutation does not necessarily mean that an individual will develop blood clots. Other genetic and environmental factors also contribute to the overall risk. Therefore, the screening results should be interpreted in the context of the individual’s overall health and medical history. |
